Use of RGM and its modulators

• US 8,680,239 B2
• Filed: 06/11/2012
• Issued: 03/25/2014
• Est. Priority Date: 12/22/2000
• Status: Active Grant

• Current Assignee: Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften e.V. (Max-Planck-Gesellschaft zur Frderung der Wissenschaften e)
• Original Assignee: Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften e.V. (Max-Planck-Gesellschaft zur Frderung der Wissenschaften e)
• Inventors: Mueller, Bernhard K., Macchi, Paolo, Bonhoeffer, Friedrich, Stahl, Bernd, Mann, Matthias, Monnier, Philippe P., Andersen, Jens S.
• Primary Examiner(s): Ballard, Kimberly A
• Application Number:
  US13/493,005
• Publication Number:
  US 20130072667A1
• Time in Patent Office: 652 Days
• Field of Search: None
• US Class Current: 530/350
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 39/02 Antidotes
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 14/465 : from birds
• CPC Class Codes: C07K 14/47 : from mammals
• CPC Class Codes: C07K 14/4702 : Regulators; Modulating activity
• CPC Class Codes: C07K 16/28 : against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to the use of a modulator of a polypeptide having or comprising an amino acid sequence as disclosed herein or of a functional fragment or derivative thereof or of a polynucleotide encoding said polypeptide or fragment or derivative for the preparation of a pharmaceutical composition for preventing, alleviating or treating diseases or conditions associated with the degeneration or injury of vertebrate nervous tissue, associated with seizures or associated with angiogenic disorders or disorders of the cardio-vascular system.

Claims

1. An isolated polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:

18, 20, 23, 25 or an amino acid sequence having more than 90% identity over a full length of SEQ ID NO;

18 or 25.

2. The isolated polypeptide of claim 1, comprising SEQ ID NO:

18 or the amino acid sequence having more than 90% identity over the full length of SEQ ID NO;

18.

3. The isolated polypeptide of claim 1, comprising SEQ ID NO:

20.

4. The isolated polypeptide of claim 1, comprising SEQ ID NO:

23.

5. The isolated polypeptide of claim 1, comprising SEQ ID NO:

25 or the amino acid sequence having more than 90% identity over the full length of SEQ ID NO;

25.